Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 18/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.50 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.50 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391436 | 0.90 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL392252 | 0.88 | MAP2K1 (0.63) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL2341603 | 0.79 | MAP2K1 (0.80) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL391878 | 0.79 | MAP2K1 (0.64) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL14748182 | 0.78 | MAP2K1 (0.65) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL13070149 | 0.78 | MAP2K1 (0.59) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL388837 | 0.78 | MAP2K1 (0.69) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL393023 | 0.78 | MAP2K1 (0.76) | MAP2K1MAP2K2MAP2K5EIF2AK1KCNH2 | |
| SCHEMBL18518902 | 0.77 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL391338 | 0.77 | MAP2K1 (0.51) | MAP2K1MAP2K2MAP2K5EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101639-B2 | 6-oxo-1,6-dihydropyridine compounds as inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110288092-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110178136-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7893065-B2 | mitogen activated protein kinase inhibitors; 4-(2-Fluoro-4-(methylthio)phenylamino)-N-(2-hydroxyethoxy)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide; used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals | ARRAY BIOPHARMA INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-1682138-B1 | HETEROCYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288092-A1 | Heterocyclic Inhibitors of MEK and Methods of Use Thereof | NRAS, BRAF, RAF1 | MAP2K1 45/4885MAP2K2 34/4885MAP2K5 57/4885 |
| US-20110178136-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | BRAF, NRAS, CDK9 | MAP2K1 138/4885MAP2K2 106/4885MAP2K5 150/4885 |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 82/4885MAP2K2 69/4885MAP2K5 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.